



WEDNESDAY, 9th NOVEMBER 2016 COMMENCING 9:30 AM
AT THE [PARK INN HOTEL CARDIFF NORTH](#), CIRCLE WAY EAST
LLANEDYRN, CARDIFF, CF23 9XF

AGENDA

- | | |
|---------------------------------------|------------------|
| | Enclosure |
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/1116 |

To protect commercial confidentiality the following appraisal will be held in private

- | | |
|--|----------------------------|
| 5. Appraisal 1: Full Submission (WPAS)
Levofloxacin (Quinsair[®]) for the management of chronic pulmonary infections due to <i>Pseudomonas aeruginosa</i> in adult patients with cystic fibrosis | 2/AWMSG/1116
Appendices |
| 6. Appraisal 2: Instructed Appraisal (WPAS)
Sofosbuvir/velpatasvir (Epclusa[®]) for the treatment of chronic hepatitis C virus (HCV) infection in adults | 3/AWMSG/1116
Appendices |

The meeting will now open to the public (approximately 11.00am)

- | | |
|---|----------------------------|
| 7. Chairman's report (verbal update) | |
| 8. Vitamins for Babies, Children and Pregnant and Breastfeeding Women | 4/AWMSG/1116 |
| 9. Review of existing advice:
Insulin detemir (Levemir[®]) for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. | 5/AWMSG/1116 |
| 10. Appraisal 4: Full Submission
Aviptadil/phentolamine (Invicorp[®]) for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology | 6/AWMSG/1116
Appendices |
| 11. National Prescribing Indicators 2016–2017 – Analysis of Prescribing Data to June 2016 | 7/AWMSG/1116 |

12. **Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG – Data to March 2016** 8/AWMSG/1116

13. **Appraisal 5: Limited Submission** 9/AWMSG/1116
Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey®) for the Appendices
treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load \leq 100,000 HIV 1 RNA copies/mL

14. **Appraisal 6: Full Submission** 10/AWMSG/1116
Dequalinium chloride (Fluomizin®) for the treatment of bacterial Appendices
vaginosis

15. **Feedback from AWPAG Meeting held 28th September 2016** 11/AWMSG/1116